MMI Investments President Clay B. Lifflander Joins Dendrite Board of Directors

  
    
  
  
    
      Dendrite International, Inc., (NASDAQ: DRTE) today announced that Clay 
      B. Lifflander has accepted the company’s 
      invitation to join its Board of Directors. Mr. Lifflander is the 
      president of the general partner of MMI Investments, which owns 13.7 
      percent of Dendrite’s outstanding shares and 
      is the company’s largest shareholder.
    
    
      "We are pleased to welcome Clay Lifflander to our Board,” 
      said John Bailye, chairman and chief executive officer of Dendrite. “We 
      have maintained an on-going dialogue with MMI as it has increased its 
      position in the company. Clay will be a fine complement to our hard 
      working and very committed Board.”
    
    
      Mr. Lifflander has been with MMI for nearly eleven years, presiding over 
      its strong growth in managed assets, which currently total approximately 
      $700 million in securities under management. Prior to joining MMI, Mr. 
      Lifflander served as President of the NYC Economic Development Corp 
      under Mayor Rudolph Giuliani and prior to that was Managing Director in 
      the M&A Group at Smith Barney.
    
    
      MMI entered into a standstill agreement as part of its acceptance of the 
      Board seat offer from Dendrite. It is expected that Mr. Lifflander will 
      also be appointed to the Nominating and Corporate Governance Committee.
    
    
      About Dendrite
    
    
      Founded in 1986, Dendrite International (NASDAQ: DRTE) enables sales, 
      marketing, clinical and compliance solutions for the global, 
      pharmaceutical industry. The company has clients in more than 50 
      countries and includes the world's top 20 pharmaceutical companies. For 
      more information, please visit www.dendrite.com.
    
    
      Note: Dendrite is a registered trademark of Dendrite International, Inc.
    
    
      This document may contain forward-looking statements that may be 
      identified by such forward-looking terminology as "expect," "believe," 
      "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," 
      and similar statements or variations. Such forward-looking statements 
      are based on our current expectations, estimates, assumptions and 
      projections and involve significant risks and uncertainties, including 
      risks which may result from our dependence on the pharmaceutical 
      industry; fluctuations in quarterly revenues due to lengthy sales and 
      implementation cycles for certain of our solutions; our fixed expenses 
      in relation to fluctuating revenues and variations in customers' budget 
      cycles; dependence on certain major customers; changes in demand for our 
      products and services attributable to any weakness experienced in the 
      economy or mergers, acquisitions and consolidations in the 
      pharmaceutical industry; successful and timely development and 
      introduction of new products and versions; rapid technological changes; 
      increased competition; international operations; integrating the 
      entities we acquire; our ability to effectively manage our growth; the 
      protection of our proprietary technology; our ability to compete in the 
      Internet-related products and services market; the continued demand for 
      Internet-related products and services; the ability of our third party 
      vendors to respond to technological change; our ability to maintain our 
      relationships with third-party vendors; less favorable than anticipated 
      results from strategic relationships; dependence of data solutions on 
      strategic relationships; events which may affect the U.S. and world 
      economies; and catastrophic events which could negatively affect our 
      information technology infrastructure. Other important factors that 
      should be reviewed and carefully considered are included in the 
      company's 10-K, 10-Qs, and other reports filed with the SEC. Actual 
      results may differ materially. The company assumes no obligation for 
      updating any such forward-looking statements to reflect actual results, 
      changes in assumptions or other changes affecting such forward-looking 
      statements.
    
  
Dendrite International, Inc., (NASDAQ: DRTE) today announced that
Clay B. Lifflander has accepted the company's invitation to join its
Board of Directors. Mr. Lifflander is the president of the general
partner of MMI Investments, which owns 13.7 percent of Dendrite's
outstanding shares and is the company's largest shareholder.

   "We are pleased to welcome Clay Lifflander to our Board," said
John Bailye, chairman and chief executive officer of Dendrite. "We
have maintained an on-going dialogue with MMI as it has increased its
position in the company. Clay will be a fine complement to our hard
working and very committed Board."

   Mr. Lifflander has been with MMI for nearly eleven years,
presiding over its strong growth in managed assets, which currently
total approximately $700 million in securities under management. Prior
to joining MMI, Mr. Lifflander served as President of the NYC Economic
Development Corp under Mayor Rudolph Giuliani and prior to that was
Managing Director in the M&A Group at Smith Barney.

   MMI entered into a standstill agreement as part of its acceptance
of the Board seat offer from Dendrite. It is expected that Mr.
Lifflander will also be appointed to the Nominating and Corporate
Governance Committee.

   About Dendrite

   Founded in 1986, Dendrite International (NASDAQ: DRTE) enables
sales, marketing, clinical and compliance solutions for the global,
pharmaceutical industry. The company has clients in more than 50
countries and includes the world's top 20 pharmaceutical companies.
For more information, please visit www.dendrite.com.

   Note: Dendrite is a registered trademark of Dendrite
International, Inc.

   This document may contain forward-looking statements that may be
identified by such forward-looking terminology as "expect," "believe,"
"anticipate," "will," "intend," "plan," "target," "outlook,"
"guidance," and similar statements or variations. Such forward-looking
statements are based on our current expectations, estimates,
assumptions and projections and involve significant risks and
uncertainties, including risks which may result from our dependence on
the pharmaceutical industry; fluctuations in quarterly revenues due to
lengthy sales and implementation cycles for certain of our solutions;
our fixed expenses in relation to fluctuating revenues and variations
in customers' budget cycles; dependence on certain major customers;
changes in demand for our products and services attributable to any
weakness experienced in the economy or mergers, acquisitions and
consolidations in the pharmaceutical industry; successful and timely
development and introduction of new products and versions; rapid
technological changes; increased competition; international
operations; integrating the entities we acquire; our ability to
effectively manage our growth; the protection of our proprietary
technology; our ability to compete in the Internet-related products
and services market; the continued demand for Internet-related
products and services; the ability of our third party vendors to
respond to technological change; our ability to maintain our
relationships with third-party vendors; less favorable than
anticipated results from strategic relationships; dependence of data
solutions on strategic relationships; events which may affect the U.S.
and world economies; and catastrophic events which could negatively
affect our information technology infrastructure. Other important
factors that should be reviewed and carefully considered are included
in the company's 10-K, 10-Qs, and other reports filed with the SEC.
Actual results may differ materially. The company assumes no
obligation for updating any such forward-looking statements to reflect
actual results, changes in assumptions or other changes affecting such
forward-looking statements.